Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Tamibarotene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rege Nephro acquires Tamibarotene assets from Syros Pharma.
    Rege Nephro acquires Tamibarotene assets from Syros Pharma.

    15 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rege-nephro-acquires-tamibarotene-related-assets-from-syros-pharmaceuticals-for-us-clinical-trials-302428431.html

    PR NEWSWIRE
    15 Apr 2025
    Share Share
    Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS
    Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112019957/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share
    Rege Nephro Completes Series B Funding For Kidney Disease Trials
    Rege Nephro Completes Series B Funding For Kidney Disease Trials

    07 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney-disease-therapy-trials-302268655.html

    PR NEWSWIRE
    07 Oct 2024
    Share Share
    Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression
    Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression

    13 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613264695/en

    BUSINESSWIRE
    13 Jun 2024
    Share Share
    Rege Nephro: Phase 2 Tamibarotene Trial In ADPKD Patient Enrollment
    Rege Nephro: Phase 2 Tamibarotene Trial In ADPKD Patient Enrollment

    28 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rege-nephro-co-ltd-announces-patient-enrollment-for-phase-ii-clinical-trial-of-tamibarotene-for-adpkd-302155910.html

    PR NEWSWIRE
    28 May 2024
    Share Share
    Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene
    Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240108581653/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share